Literature DB >> 15028820

Decimal point--osteoporosis therapy at the 10-year mark.

Gordon J Strewler1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028820     DOI: 10.1056/NEJMp048017

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Oral antiresorptive therapy.

Authors:  Ira Pande; David J Hosking
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

Review 2.  Oral antiresorptive therapy.

Authors:  Ira Pande; David J Hosking
Journal:  Curr Osteoporos Rep       Date:  2004-12       Impact factor: 5.096

3.  Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).

Authors:  E Landfeldt; O Ström; S Robbins; F Borgström
Journal:  Osteoporos Int       Date:  2011-02-01       Impact factor: 4.507

4.  X-irradiation-induced cell cycle delay and DNA double-strand breaks in the murine osteoblastic cell line OCT-1.

Authors:  Patrick Lau; Christa Baumstark-Khan; Christine E Hellweg; Günther Reitz
Journal:  Radiat Environ Biophys       Date:  2010-03-16       Impact factor: 1.925

5.  Osteoclast abnormalities in fractured bone during bisphosphonate treatment for osteoporosis: a case report.

Authors:  V J V Vigorita; J S Silver; E O E Eisemon
Journal:  Skeletal Radiol       Date:  2012-04-18       Impact factor: 2.199

Review 6.  Safety considerations with bisphosphonates for the treatment of osteoporosis.

Authors:  William Strampel; Ronald Emkey; Roberto Civitelli
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Authors:  Kuntheavy Ing-Lorenzini; Jules Desmeules; Olivier Plachta; Domizio Suva; Pierre Dayer; Robin Peter
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.

Authors:  Andrew Deane; Leonor Constancio; Ignac Fogelman; Geeta Hampson
Journal:  BMC Musculoskelet Disord       Date:  2007-01-10       Impact factor: 2.362

9.  Polycan, a β-glucan from Aureobasidium pullulans SM-2001, mitigates ovariectomy-induced osteoporosis in rats.

Authors:  Mi Young Jung; Joo Wan Kim; Ki Young Kim; Seong Hun Choi; Sae Kwang Ku
Journal:  Exp Ther Med       Date:  2016-06-27       Impact factor: 2.447

10.  Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database.

Authors:  Tao Fan; Qiaoyi Zhang; Shuvayu S Sen
Journal:  Clinicoecon Outcomes Res       Date:  2013-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.